
Opinion|Videos|April 25, 2024
Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis
Expert perspectives on androgen receptor signaling and its role in fueling prostate cancer metastasis along with a whiteboarding animation depicting this process.
Advertisement
Episodes in this series

Advertisement
Related to this article

Panelists answer audience questions on treatment targets, fertility-sparing options, and formulations, and why lifestyle change and therapy pair well.

Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.

Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.

Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.

Mohit Khera, MD, MBA, MPH, discusses preliminary research on radiofrequency therapy as a potential treatment for vasculogenic erectile dysfunction.

Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Advertisement
Advertisement
Trending on Urology Times
1
LIB-01 enters phase 2b development for erectile dysfunction
2
Treatment Targets, Formulations, and the Future of Testosterone
3
Jonathan Rosenberg, MD, reacts to FDA approval of durvalumab plus EV for MIBC
4
Prostate Cancer, BPH, and Testosterone Scheduling Myths
5

